Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks and strokes in survivors.

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Moana's island home of ...

For example, should such glucose lowering drugs be discontinued at the point of remission, and can specific drug mechanisms be harnessed for a more individualized approach to remission of type 2 ...

and can specific drug mechanisms be harnessed for a more individualised approach to remission of type 2 diabetes? Despite these uncertainties, they note that SGLT-2 inhibitors are now co-first ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

Opens in a new tab or window Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors from 2014 to 2020. Real-world outcomes largely point to comparable ...